Migraine after steroid-treated childhood eczema: suppression history, potency and direction of cure
A 41-year-old schoolteacher consults for migraine that began at menarche and now occurs 3–4 times a month, each attack lasting 18–24 hours. Attacks are right-sided and throbbing, worse from light, noise and perfume, and relieved by firm pressure and a cold pack; vomiting marks the peak. She recalls flexural eczema from age 3 to 10 treated continuously with topical betamethasone; it cleared completely at 11 and the migraine began at 13. Between attacks she is mildly chilly, thirstless, weepy at films, and sleeps poorly for two nights before an attack. She has used sumatriptan for 6 years, taking 8–10 tablets a month, and wants to stop it. BP 118/76, weight 58 kg, no other medication. She asks whether the eczema "going inward" caused the migraine and whether homoeopathy can prevent attacks.
1. How should the suppression narrative be handled in case-taking, and how much should it influence the prescription?
Read the worked answer
Take the history seriously, but do not let a causal story replace the totality.
- Record the sequence precisely: age of onset, duration of topical steroid use, age of clearance, interval before migraine, and any other suppressed discharges since. This is valuable for prognosis and for the follow-up plan.
- Explain honestly that a link is plausible and commonly described clinically, but cannot be proven in an individual; she should not be led to believe that restoring eczema would cure the migraine.
- The prescription is not chosen from the story. It is chosen from the present characteristic totality: right-sided throbbing pain, worse light, noise and odour, better pressure and cold, vomiting at the peak, thirstless, chilly, weepy, anticipatory sleeplessness. The suppression history changes what you avoid (further topical or systemic suppression wherever safely possible) and what you watch for on follow-up, not which remedy you select.
- If a dermatologist later needs potent topical steroids for a severe flare, coordinate rather than forbid; do not create an adversarial split in her care.
Reasoning: the aim is to treat the whole patient and to anticipate the return of old symptoms, not to reverse a historical event.
2. State the potency, dose and repetition for the first prescription in this chronic, moderately sensitive patient, with your reasoning, and give a review interval.
Read the worked answer
Prescription plan: the constitutional remedy in the 30C, one dose, dry, on an empty stomach; review in 2 weeks by telephone and in 4 weeks in person.
Reasoning:
- She is chronic, not acutely ill, with a clear but not extreme picture, and is likely to be moderately sensitive. A 30C single dose gives a measurable response without a long aggravation.
- Daily or twice-daily repetition of a 30C in a chronic case is not justified at the first prescription; the response to a single dose is itself diagnostic information (Organon §246).
- A 200C as a first prescription is defensible if the characteristic picture is very clear and the patient robust; it is not the safer default here, where a significant aggravation would be hard to interpret alongside sumatriptan use.
- Reserve LM potencies for a patient who proves sensitive after a 30C trial.
Do not stop sumatriptan abruptly. Tell her to continue it as rescue for now and to keep a simple diary (attack frequency, severity, rescue tablets, sleep, skin). Objective markers over 8–12 weeks decide continuation, potency change or a change of remedy better than a single consultation impression.
3. At 6 weeks she reports attacks reduced from 3–4 a month to 1 a month, but an itchy vesicular rash has appeared on both antecubital fossae. Interpret and act.
Read the worked answer
This is the pattern clinicians label as a favourable direction of cure (Hering's law): an improvement in the more recent, deeper or more distressing complaint followed by the reappearance of an older complaint, moving from within outward.
Action:
- Do not suppress the rash with topical steroid. Explain the pattern in advance so that she does not panic and abandon treatment.
- Do not repeat the remedy yet. Improvement is still continuing, and repetition while improvement is in progress risks obscuring the picture (Organon §246).
- Document the date of the skin eruption, its site, and the exact change in migraine frequency, so that later decisions rest on records rather than memory.
- Second prescription is made when improvement clearly stops: repeat the same remedy in the 30C (or move to a 200C if the response was good but brief), not before.
- Review at 4 weeks. If the rash is severe, unremitting, or accompanied by new general symptoms, reconsider the remedy rather than assuming cure is proceeding.
Reasoning: not every new symptom is an aggravation, and not every old symptom returning is success; the deciding evidence is the simultaneous improvement in the main complaint plus the patient's general wellbeing.